PNPLA3 and metabolic dysfunction-associated steatotic liver disease: In fact, patients with NAFLD and MetS had the lowest whole efflux capacity, 7.4% lower than that observed in patients without MetS and 22% lower than that observed in PNPLA3-driven NAFLD group.